| Company type | Public |
|---|---|
| Nasdaq: CERE Russell 2000 Component | |
| Industry | Biopharmaceuticals |
| Founded | 2018 |
| Fate | Acquired by AbbVie (Pending) |
| Headquarters | , United States |
| Website | cerevel |
Cerevel Therapeutics Holdings, Inc. is a biotechnology and pharmaceuticals company focused on the development of novel therapies for mental and neurological illnesses.[1] Cerevel was established in October 2018, and is headquartered in Cambridge, Massachusetts.[2]
The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital.[3][4]
In December 2023, AbbVie, an American pharmaceutical company, announced its intention to acquire Cerevel for US$8.7 billion.[5][6][7]
YouTube Encyclopedic
-
1/2Views:1 969784
-
Is AbbVie Stock a Buy Now!? | ABBV Stock Analysis!
-
June 29th, 2021 - Jumia (JMIA stock): Buy the dip?
Transcription
Pipeline
Cerevel uses novel approaches and technologies to develop its own drugs and treatment therapies. Its pipeline contains an array of drugs and therapies treating a range of conditions including Schizophrenia, Parkinson's, Epilepsy, mood disorders, and more.[8]
Notable Cerevel drugs and treatments at varying stages of development include:
- Tavapadon (Parkinson's)[9]
- Emraclidine (Schizophrenia, Alzheimer's)[10]
- Darigabat (Epilepsy)[11]
- CVL-871 (Dementia, Apathy)[12]
- CVL-354 (Major depressive and Substance-related disorders)[13]
Approach to Treatment
Cerevel's tagline mission statement is to "unravel the mysteries of the brain" to treat neurological disease.[14] Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types.[1]
The company has stated its approach to neurotherapy development can be viewed through three key lenses:
- "Targeted Neurocircuitry:" Development of treatment opportunities by precisely identifying and targeting the neurocircuitry that underlies a given neurological disease.[1]
- "Receptor subtype selectivity:" Selective targeting of only the relevant receptor subtype(s) related to the physiology of the disease being treated. This has the impact of minimizing undesired off-target and side effects, while maximizing activity.[1]
- "Differentiated pharmacology:" The design of full and partial agonists, antagonists and allosteric modulators that can precisely fine-tune the receptor pharmacology and neurocircuit activity, without over-activation or over-suppression of the endogenous physiologic range.[1]
References
- ^ a b c d e "The Last Frontier of Medicine". Neurology live. 2023-04-21. Retrieved 2024-01-13.
- ^ Logan, Tim (August 7, 2019). "Pfizer spinoff Cerevel moving into Cambridge Crossing". The Boston Globe. Retrieved 2024-01-13.
- ^ "Bain Capital And Pfizer Create New CNS Company Cerevel Therapeutics". markets.businessinsider.com. 2024-01-12. Retrieved 2024-01-13.
- ^ Brodwin, Erin. "Drug giant Pfizer isn't ready to abandon neuroscience — here's its $150-million 'star cluster' strategy for betting on promising brain drug startups". Business Insider. Retrieved 2024-01-13.
- ^ Constantino, Annika Kim (2023-12-06). "AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion". CNBC. Retrieved 2024-01-13.
- ^ Armstrong, Annalee (December 6, 2023). "AbbVie adds to neuroscience portfolio with $8.7B deal to acquire Cerevel". Fierce Biotech. Retrieved January 13, 2024.
- ^ "AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline". AbbVie News Center. Retrieved 2024-01-13.
- ^ "EMPOWERing the Next Generation". Psychiatric Times. 2023-09-13. Retrieved 2024-01-13.
- ^ "Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson's Disease – Cerevel Therapeutics". www.cerevel.com. 2020-01-14. Retrieved 2024-01-13.
- ^ "Emraclidine – Cerevel Therapeutics". www.cerevel.com. 2020-01-04. Retrieved 2024-01-13.
- ^ "Cerevel Therapeutics Announces Publication of Phase 2a Study Results in Neurology on Its Most Advanced Investigational Epilepsy Treatment – Cerevel Therapeutics". www.cerevel.com. 2019-04-09. Retrieved 2024-01-13.
- ^ "CVL-871 – Cerevel Therapeutics". www.cerevel.com. 2020-01-02. Retrieved 2024-01-13.
- ^ "CVL-354, a novel, brain penetrant and selective kappa opioid receptor antagonist – Cerevel Therapeutics". www.cerevel.com. 2022-12-01. Retrieved 2024-01-13.
- ^ "EX-99". www.sec.gov. Retrieved 2024-01-13.
This page was last edited on 11 April 2024, at 02:45